Form 4: Cytek Biosciences Director Deborah Neff Reports Stock and Option Awards

Director Deborah Neff reports acquisition of restricted stock units and stock options in Cytek Biosciences.

Summary

• On June 5, 2024, Deborah J. Neff, a director of Cytek Biosciences, reported the acquisition of 15,706 Restricted Stock Units (RSUs) and 23,076 stock options.
• The RSUs vest on June 5, 2025, and each RSU represents the right to receive one share of Cytek Biosciences common stock.
• The stock options, with an exercise price of $5.73, were also granted on June 5, 2024, and expire on June 5, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reflects standard executive compensation practices. The grant of equity can be seen as a positive sign of alignment between management and shareholder interests, but it's a routine event.

Positives

• The acquisition of RSUs and stock options by a director signals confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting and expiration dates of the granted securities.

Industry Context

This filing is a routine disclosure related to executive compensation and is common in the biotechnology industry.

Stakeholder Impact

• The grant of RSUs and stock options aligns the director's interests with those of the shareholders, incentivizing her to work towards increasing the company's value.

Key Dates